Top

Strahlentherapie und Onkologie

Published in:

01-02-2016 | Literatur kommentiert

Prognosebestimmung mit Genexpressionsanalysen

Konsequenzen für die Indikation zur Radiotherapie?

Authors: Dr. med. René Baumann, Dr. med. David Krug

Published in: Strahlentherapie und Onkologie | Issue 2/2016

Auszug

Fitzal F, Filipits M, Rudas M et al (2015) The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer 112:1405–1410 …

Dubsky P, Brase JC, Jakesz R et al (2013) The EndoPredict score provides prognostic information on late distantmetastases in ERþ/HER2- breast cancer patients. Br J Cancer 109:2959–2964PubMedPubMedCentralCrossRef

Dubsky P, Filipits M, Jakesz R et al (2013) EndoPredict improves the prognostic classification derived from commonclinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 24:640–647PubMedPubMedCentralCrossRef

Filipits M, Rudas M, Jakesz R et al (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 18:6012–6020CrossRef

Liu FF, Shi W, Done SJ et al (2015) Identification of a low-risk luminal A breast cancer cohort that may not benefit from breast radiotherapy. J Clin Oncol 33:2035–2040PubMedCrossRef

Mamounas EP, Tang G, Fisher B et al (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677–1683PubMedPubMedCentralCrossRef

Ontario Clinical Oncology Group (OCOG) A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer (LUMINA); ClinicalTrials.gov Identifier: NCT01791829

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecularportraits of human breasttumours. Nature 406:747–752PubMedCrossRef

Tramm T, Kyndi M, Myrhe S et al (2014) Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. Acta Oncol 53:1337–1346PubMedCrossRef

Title: Prognosebestimmung mit Genexpressionsanalysen
Konsequenzen für die Indikation zur Radiotherapie?
Authors: Dr. med. René Baumann
Dr. med. David Krug
Publication date: 01-02-2016
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 2/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-015-0931-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognosebestimmung mit Genexpressionsanalysen

Konsequenzen für die Indikation zur Radiotherapie?

Auszug

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 2/2016

Image-guided intensity-modulated radiotherapy of prostate cancer

Scanned ion beam therapy for prostate carcinoma

IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC

Lipiodol versus diaphragm in 4D-CBCT-guided stereotactic radiotherapy of hepatocellular carcinomas

Tomotherapy PET-guided dose escalation

Cone-beam CT-guided radiotherapy in the management of lung cancer